Reviewing Pulse Biosciences (NASDAQ:PLSE) and Competitive Technologies (OTCMKTS:CTTC)

Pulse Biosciences (NASDAQ:PLSE) and Competitive Technologies (OTCMKTS:CTTC) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Institutional and Insider Ownership

76.9% of Pulse Biosciences shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Comparatively, 17.5% of Competitive Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Pulse Biosciences and Competitive Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
Competitive Technologies	N/A	N/A	N/A

Valuation and Earnings

This table compares Pulse Biosciences and Competitive Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$1.19 million	2,944.78	-$72.78 million	($1.18)	-42.73
Competitive Technologies	N/A	N/A	N/A	N/A	N/A

Competitive Technologies has lower revenue, but higher earnings than Pulse Biosciences.

Analyst Ratings

This is a breakdown of current ratings and target prices for Pulse Biosciences and Competitive Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1	0	4	0	2.60
Competitive Technologies	0	0	0	0	0.00

Pulse Biosciences presently has a consensus price target of $45.25, indicating a potential downside of 10.25%. Given Competitive Technologies’ higher possible upside, analysts plainly believe Competitive Technologies is more favorable than Pulse Biosciences.

Summary

Pulse Biosciences beats Competitive Technologies on 5 of the 9 factors compared between the two stocks.

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

About Competitive Technologies

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.